An observational study in Hypertension, Primary Aldosteronism and Urine Aldosterone, sponsored by Dr Ian B Wilkinson. Recruiting at 1 site in United Kingdom. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2023-09-21.
Sponsored by Dr Ian B Wilkinson · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 223 studies in Hypertension with a site in United Kingdom — 34 open to participants now, 43 under way, 7 of them phase 3. Hypertension · United Kingdom.
Among the 223 studies in Hypertension with a site in United Kingdom, this one is the 34th largest by planned enrollment of the 50 observational ones that give a count, is one of 13 that started in 2023, is one of 50 observational ones, reaches primary completion later than 5 of the 42 other live ones, and was the 185th registered.
6,128 studies on the registry are indexed under Hypertension; 907 are open to participants now.
Browse Hypertension studies →34 of the 223 studies in Hypertension with a site in United Kingdom are open now. Recruiting first, the newest first:
CRISPR Therapeutics AG · Sites in United Kingdom, United States, Australia
Ages 18–75
King's College London · Sites in United Kingdom
Ages 10–25 · Healthy volunteers
Northumbria University · Sites in United Kingdom
Ages 18+
Cambridge University Hospitals NHS Foundation Trust · Sites in United Kingdom
Ages 18–40
Medtronic Vascular · Sites in United Kingdom, Australia, Belgium and 6 more countries
Ages 18+
A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →
Of the 552 Hypertension studies recruiting now, 260 (47%) set no upper age limit and 198 (36%) stop at 75 or younger; 40 take children under 18; 136 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
223 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 6 · Phase 2 27 · Phase 3 48 · Phase 4 20
First in 1997; this study’s year is marked. 13 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 120 is below the median of 352 across 1,166 observational studies indexed under Hypertension.
Median enrollment 125 across the 172 interventional studies, 200 across the 50 observational. Of the 156 that completed or were terminated, 52 (33%) have results posted.
This tab as a report to print or save as PDF → With an account.
97 of 223 have an industry lead sponsor. The 10 most frequent:
Dr Ian B Wilkinson is the lead sponsor of 2 studies on the registry; 2 are open to participants now.
Dr Ian B Wilkinson has 1 study filed under Hypertension — fewer than ten, so there is no comparison to draw.
11 of the studies in Hypertension with a site in United Kingdom that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03683186Phase 3United TherapeuticsA Study Evaluating the Long-Term Efficacy and Safety of Ralinepag in Subjects With PAH Via an Open-Label Extension | 2026-12 |
| NCT07222917AstraZenecaA Phase IIb Study to Evaluate the Effect of Dapagliflozin in Combination With Baxdrostat Compared With Baxdrostat on Albuminuria in Participants With Chronic Kidney Disease and High Blood Pressure. | 2026-12-10 |
| NCT07294794University of BirminghamPersonalised Pharmacometabolomic-guided Strategy Trial to Optimise Treatment for Hypertension | 2026-12-31 |
| NCT06059638Orchestra BioMed, IncBradycArdia paCemaKer With AV Interval Modulation for Blood prEssure treAtmenT | 2027-01 |
| NCT06823115Indiana UniversityAssessment of Worldwide Acute Kidney Injury Epidemiology in Neonates 2.0 | 2027-01 |
Add all 11 to your calendar (.ics) → With an account.
Among the 223 studies in Hypertension with a site in United Kingdom, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is an observational study compares the positivity rates of two tests for screening for primary aldosteronism: plasma aldosterone renin ratio and 24-hour urine aldosterone in patients with young-onset hypertension with or without other clinical features of primary aldosteronism.
Plasma aldosterone and renin measurements are subject to significant intra-individual variability, including variation related to posture, time of day and sodium balance. Aldosterone secretion is not constant and may be subject to diurnal variation. As such one-off testing of ARR, does not consider the salt status of the individual necessitating repetition of tests to ensure false negative or false positive test results are ruled out. The value of accumulated aldosterone in a 24-hour sample has the advantage that it does not depend on circadian variation. This pilot observational study will help establish the positivity rates of both standard plasma aldosterone renin ratio and 24-hour urine aldosterone, and the degree to which they correlate but will help establish if untargeted screening in young-onset hypertension is feasible and test the robustness of current standard guidelines for primary aldosteronism screening and case confirmation.
To enable the inclusion of a diverse population, representative of the UK in terms of ethnicity, and geographical and environmental factors that affect blood pressure and PA, we aim to conduct the study at several specialist hypertension sites in the UK. We will recruit patients referred to one of the study sites with hypertension (NICE definition) who fall into one of the following groups (cohorts):
Cohort 1: Adult patients (18-75 years of age) with onset hypertension (≤60 years of age) but without other obvious features of PA Cohort 2: Adult patients (18-75 years of age) with onset hypertension (≤60 years of age) with one of the features: low serum potassium, or resistant hypertension.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
A patient will be eligible for inclusion in this trial only if all of the following criteria apply:
Exclusion Criteria:
Severe hypertension (sustained blood pressure of >200/110 mmHg) or a history of known secondary hypertension other than PA.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Rates of positive and negative, Aldosterone renin ratio and 24-hr urine aldosterone in unselected patients with hypertension and in patients with suspected primary aldosteronism
Time frame: 1 year
Degree of agreement between a positive/negative ARR and a positive/negative 24-hr urine aldosterone
Time frame: 1 year
Number of patients who required oral salt loading
Time frame: 1 year
The predictive value of a positive aldosterone renin ratio or 24-hr urine aldosterone with a positive confirmatory test
Time frame: 1 year
Plan to share: No
No publications or documents are linked to this record.
Start is estimated for Sep 2023; primary completion for Sep 2024, 12 months later.
Of 348 non-industry observational studies under Hypertension, half reached primary completion within 44 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 111. This study's planned 12 months is below that.
Counting every sponsor, half of 429 studies reached it within 38 months; a quarter within 17 and three quarters within 96.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Dr Ian B Wilkinson